The switch to the biosimilars of Humira (adalimumab) is beginning to slow the cost per claim of specialty drugs, according to the latest Specialty Spend and Trend report published by Pharmaceutical Strategies Group (PSG).

Although Humira continues to be a top specialty drug by spend, the 10 biosimilars that reference Humira are starting to have an impact. In 2024, the Humira biosimilars accounted for 14.1% market share, which represents a substantial shift compared with 2023. Continuing into 2025 and beyond, this percentage will continue to increase, PSG said.

“In 2023, the Humira biosimilars had a 1% market share,” Morgan Lee, Ph.D., MPH, senior director of Research & Strategy at PSG, said during an interview. “Now, it’s just over 14%. Other biosimilars continue to get more market sha

See Full Page